Genetics of bone loss in rheumatoid arthritis—role of vitamin D receptor polymorphisms

RA is a systemic inflammatory arthritis that leads to local and systemic bone loss. Osteoporosis or the systemic bone loss associated with RA increases the risk for fragility fractures, which can affect quality of life dramatically in RA patients. Although traditional and RA-related risk factors hav...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2009-04, Vol.48 (4), p.342-346
Main Author: Ranganathan, P.
Format: Article
Language:English
Subjects:
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - genetics
Biological and medical sciences
Bone loss
Diseases of the osteoarticular system
Fractures, Bone - etiology
Fractures, Bone - genetics
Genetic Predisposition to Disease
Genotype
HLA-DR Antigens
HLA-DRB1 Chains
Humans
Inflammatory joint diseases
Medical sciences
Osteoporosis - complications
Osteoporosis - genetics
Osteoporosis. Osteomalacia. Paget disease
Polymorphism
Polymorphism, Genetic
Receptors, Calcitriol - genetics
Reviews
Rheumatoid arthritis
Vitamin D receptor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RA is a systemic inflammatory arthritis that leads to local and systemic bone loss. Osteoporosis or the systemic bone loss associated with RA increases the risk for fragility fractures, which can affect quality of life dramatically in RA patients. Although traditional and RA-related risk factors have been defined and studied for osteoporosis associated with RA, genetic factors such as polymorphic variants in the traditional candidate genes for osteoporosis, such as the vitamin D receptor (VDR), type 1 collagen A1 (COLIA1) and oestrogen receptor-α (ESR1), have not been well elucidated in RA patients. This review summarizes the currently available literature on the association of VDR polymorphisms with local and systemic bone loss in RA. It also discusses potential targets for genetic research in this area, such as polymorphisms in genes, such as IL-6 (IL6) and TNF receptor type 2 (TNFRSF1B), which control the inflammatory response in RA and may influence bone loss in RA. Defining such genetic factors, in addition to traditional and RA-related risk factors for osteoporosis in RA, may facilitate early identification of patients at high risk for fractures who can then be targeted for treatment.
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/ken473